Adakveo (Crizanlizumab) specifically is a selectin blocker used in order to decrease the frequency of VOCs (Vaso-Occlusive Crises) in adults and pediatric patients aged sixteen years and older with SCD (Sickle Cell Disease).
Dosage: Administer crizanlizumab dose 5 mg per kg by intravenous infusion over a period of 30 minutes at 0, 2, and every 4 weeks thereafter. In case a dose is missed, administer Crizanlizumab promptly. In case Crizanlizumab injection is administered within a couple of weeks following the missed dose, dosing must be continued on behalf of the patient’s apt or original schedule. If Crizanlizumab injection is administered more than a couple of weeks following the missed dose, dosing should be continued every four weeks thereafter. Crizanlizumab may be given either with or without hydroxyurea.
Side Effects: The most commonly reported crizanlizumab side effects include:
- Back pain
Warnings and Precautions:
- It is advised that crizanlizumab should be prepared and administered by an experienced healthcare practitioner.
- Crizanlizumab-tmca is intended as a long-term therapy. Patients will be regularly monitored by their health care team for their condition and treatment plan.
- Monitor patients with adakveo drug for signs/symptoms of infusion-related reactions including vomiting, fever, chills, nausea, fatigue, dizziness, pruritus, sweating, urticaria, shortness of breath or wheezing.
- Inform your doctor that you are on adakveo before having any blood tests. Adakveo could interfere with a laboratory test in order to measure your platelet counts.
- Before crizanlizumab use, remember to tell your doctor about all of your medical conditions, including if you’re pregnant or want to become pregnant. It is not known if this drug may harm your unborn baby.